ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

Jeffrey S. Weber, MD, PhD, highlighted key efficacy findings from the mRNA-4157-P201/KEYNOTE-942 trial, expanded on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma, and underscored the importance of continued research on mRNA vaccines paired with standard PD-1 therapy across cancer types.

Related Keywords

Australia ,United States ,Jeffreys Weber , ,Perlmutter Cancer Center ,Department Of Medicine ,York University ,Melanoma Research Program ,Grossman School Of Medicine ,New York University ,Isaac Perlmutter Professor ,Mrna Vaccine ,Pembrolizumab ,Melanoma ,Ctdna ,High Risk ,Jesmo ,